Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary

Print

| AAA

Active Healthcare Stocks ETF TMED Spiked in 1H

BY | ETF Database

6:43 am ET 07/17/26 | 8 VIEWS

Related Symbols
TMED

Healthcare stocks have boosted the ETF space in recent weeks. Despite some potential headwinds, the sector and its related thematic ETFs, like active healthcare ETF TMED, have performed. TMED spiked in June specifically, and may offer a potent satellite offering for portfolios combining defensive and disruptive aspects.Key Takeaways: TMED’s active approach has helped it return 18.6% YTD, outperforming both its benchmark index and the ETF Database category’s average. The strategy charges a competitive fee of 44 basis point (bps) to do so. TMED has benefitted from positive news this year for its top holding, LLY, and could help diversify portfolios. The T. Rowe Price Health Care ETF (TMED ) actively invests in healthcare stocks, charging a 44-bps fee. The strategy has returned 18.6% YTD, outperforming the ETF Database Health and Biotech Equities Category average in that time. TMED looks to outperform its benchmark the S&P Health Care Select Sector Index. That index has returned just 5.7% YTD. The active ETF leans on T. Rowe Price’s fundamental research capabilities to assess a wide pool of global equities. Specifically, the strategy scrutinizes healthcare firms active in subcategories like pharmaceuticals, biotech, and medical devices. Eligible stocks include those classified in the MSCI GICS health care sector. Together, with a bottom up approach, TMED managers invest in growth or value as needed. See more: T. Rowe Price’s Love Discusses ETFs Hitting 3-Year Mark TMED currently holds Eli Lilly (LLY) as its largest stock. LLY has returned 4.6% over the last month alone. The stock leapt in recent weeks as analysts continued to tout growing demand for weight loss drugs. LLY, of course, is responsible for major GLP-1 products like Mounjaro and Zepbound. Looking ahead, while rates may stay on track this year, cuts could loom in 2027. Combined with the ETF’s active adaptability, it could be a solid addition, with time to ramp up into further performance next year. What’s more, the fund could help add some diversification away from the huge role of tech and AI stocks in many portfolios. Overall, TMED may be one to watch in the second half. For more news, information, and analysis, visit our Active ETF Content Hub.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.